GLP1_NEW
MEDI4166 200 mg injection once weekly
MEDI41_SC_200MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.66 (0.01 to 44.26) | 0.55 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.16 (0.00 to 3.36) | 0.89 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.53 (0.08 to 2.79) | 0.80 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.09 (0.00 to 1.26) | 0.91 |